A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with pembrolizumab and cetuximab for the treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)treatment-naïve participants for R/M disease, programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1
Type d'étude : RIPH1